What has ibogaine done for depression?

Depression scores in the Stanford cohort fell from 25.6 to 2.8 within days of treatment, and stood at 3.8 a month later [1]. Most participants met the threshold for remission [1]. The study had thirty people in it, no control group, and depression was not what it set out to measure [1].

What was measured

The instrument was MADRS, the Montgomery-Asberg Depression Rating Scale, administered by a clinician rather than filled in by the participant [1].

Assessments took place two to three days before treatment, four to five days after, and one month after [1]. Of the thirty participants, fifteen met criteria for major depression at baseline [1].

The participants were male US Special Operations Forces veterans with a history of repeated traumatic brain injury, averaging 38.6 lifetime head injuries [1]. Depression in that group frequently accompanies the head injuries and the PTSD rather than standing alone.

The size of the change

MADRS scores fell from 25.6 at baseline to 2.8 immediately after treatment, and were 3.8 at one month [1]. The effect sizes were 2.65 and 2.80 [1].

A score of 25.6 sits in the moderate range. A score under 10 is generally taken as remission, and the one-month figure is well inside it.

In the exploratory analysis, 83 per cent of participants met remission criteria on MADRS at one month, and the mean reduction was 87 per cent [1]. Anxiety scores moved similarly, falling from 20.8 to 3.9 at one month [1].

The authors label those remission and response figures exploratory, and caution that they should be interpreted carefully [1]. That is their own framing rather than a criticism added afterwards.

In the twelve-month follow-up, which has not been peer reviewed, the estimated probability of sustained remission from depression at a year was 66 per cent [2]. That is lower than the figure for PTSD in the same analysis, which was 84 per cent [2].

The finding on suicidal thinking

One result deserves separating from the rest, because of what it concerns.

At baseline, 47 per cent of participants reported some degree of suicidal thinking on the relevant MADRS item [1]. Immediately after treatment that figure was zero, and at one month it was 7 per cent [1].

Nineteen of the thirty had experienced suicidal thinking before the study, and seven had made an attempt [1]. This was not a group at low risk.

The authors describe this as exploratory and say it must be interpreted cautiously [1]. It is a single item on a depression scale, in thirty people, without a comparison group. It is also the kind of finding that justifies careful further work rather than being set aside.

The recurrences the authors recorded

The paper notes that several participants had a recurrence of notable symptoms between assessment points [1].

That detail rarely survives into summaries, and it changes the shape of the result. The one-month figures are snapshots, and a snapshot taken on a good day does not describe a month that contained bad ones.

It also fits what is known about depression generally, which fluctuates. A treatment that produces a large average improvement can still leave a person with difficult weeks inside it.

Anyone weighing this evidence should hold both facts together. The average change was large and sustained in most of those followed up, and individual courses were not uniformly smooth.

This was not a depression study

The Stanford cohort was recruited for traumatic brain injury, and the primary outcome was functional disability rather than mood [1].

Depression was measured alongside PTSD and anxiety as a secondary outcome in a population where all three overlap heavily [1]. Fifteen of thirty met depression criteria, and twenty-three met PTSD criteria [1].

That overlap makes attribution difficult in a particular way. When PTSD improves substantially, depression scores commonly fall with it, because the two share symptoms such as sleep disturbance, withdrawal and loss of interest.

So the honest description is narrow: depression scores improved in a group whose PTSD also improved markedly, and the study cannot separate the two. It is not a finding about depression on its own.

What a MADRS score describes

Understanding what moved requires knowing what the scale covers, because a number falling from 25.6 to 3.8 is otherwise abstract.

MADRS has ten items, each rated from zero to six by a clinician after an interview. They cover apparent sadness and reported sadness, inner tension, reduced sleep, reduced appetite, difficulty concentrating, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.

Several of those items overlap directly with PTSD and with the aftermath of repeated head injury. Sleep disturbance, concentration difficulty and lassitude appear in all three conditions, and a participant whose sleep improved would score lower on the depression scale whether or not their mood was what changed.

That is not a flaw in the instrument, which was designed to track change in depression rather than to distinguish it from neighbouring conditions. It is a reason to read a large fall in a population with heavy comorbidity as less specific than the same fall in a cleanly depressed group.

The inability-to-feel item is worth singling out. Emotional numbing is a core PTSD symptom and a core depression symptom, and the qualitative work from this cohort describes participants experiencing surges of emotion during treatment. Movement on that item could reflect either condition, or the experience itself.

None of this makes the change smaller than reported. It makes the label on the change less certain than a headline suggests, and the authors' own framing of the remission figures as exploratory reflects the same caution [1].

What the wider evidence says

A 2026 review of thirty years of human ibogaine research reached a consistent conclusion. The positive efficacy data comes mostly from uncontrolled studies [3].

That describes the field as a whole and not this cohort alone. Across three decades, the human work has largely been observational series, retrospective chart reviews and open-label pilots.

For depression specifically, the evidence base is thinner still. There is no published trial of ibogaine for depression as a primary indication, controlled or otherwise. What exists is depression measured alongside something else.

Why no controlled trial has tested this

Three obstacles sit in the way, and none is simply a lack of interest.

The first is blinding. Ibogaine produces effects impossible to mistake for an inactive pill, including ataxia severe enough that patients cannot walk unaided [4]. Both participant and assessor know what was given, which is why an active comparator is usually proposed.

The second is cardiac risk. A trial must justify exposing participants to a drug that lengthens the QT interval by an average of 95 milliseconds, with half passing 500 milliseconds in one cohort [4]. For depression, where effective treatments already exist, that justification is harder than for a condition with none.

The third is the package problem. In the Stanford protocol the dose came with magnesium, therapist coaching before and after, group ceremonial activities, bodywork and structured integration [1]. A trial of ibogaine alone would test something different from what produced these results.

How this sits beside existing treatment

Depression already has treatments with controlled evidence behind them, which changes how an uncontrolled finding should be read.

Where a condition has no effective treatment, a large uncontrolled signal carries more practical weight, because the alternative is nothing. Depression is not in that position for most people, even if a particular person has not yet found something that works for them.

This matters for the risk calculation rather than the interest of the science. The cardiac exposure is the same whatever the indication, and the threshold for accepting it reasonably rises when other options remain untried.

It also shapes what a careful provider should say. Treatment-resistant depression is a real category, and it is not the same as depression that has been treated once without success.

What a reader can take from this

Someone reading this because of their own depression faces a gap between the question they are asking and the question the study answers.

The study reports that a group of combat veterans with repeated head injuries, severe PTSD and co-occurring depression improved markedly after a week-long programme built around ibogaine. It does not report what happens to depression in someone without that history, nor what the drug contributes separately from the programme.

The participants also stopped all psychiatric medications before treatment [1]. For anyone currently taking an antidepressant, that step is part of the protocol being described and carries its own risks, including the possibility of worsening before any treatment begins.

The association between experience intensity and outcome seen in the same cohort points the same way [5]. If what happens during and around the session shapes the result, a session without that surrounding care is not the thing that was studied.

One further caution belongs here, because it is specific to depression rather than general. The treatment described involves travelling, usually abroad, and spending a week in an unfamiliar setting among strangers. For someone whose depression includes difficulty leaving the house, that journey is not a neutral preliminary, and the people who completed it were by definition able to undertake it.

Cost compounds the same selection. Participants in this cohort had their treatment funded by a veterans' nonprofit [1]. People paying their own way are a different group again, and an expensive, effortful, self-selected intervention attracts those with the resources and the determination to pursue it, both of which predict better outcomes on their own.

Where the research goes next

Three steps would turn this from a signal into an answer. A cohort recruited for depression rather than brain injury. A comparison group, whether an active comparator or a waiting list with equivalent surrounding care. And follow-up long enough to capture the recurrences the authors already noted [1].

Until those exist, the evidence overview places these numbers beside the rest of the human findings, and the close read of the MISTIC study goes through the protocol in detail.

Frequently asked questions

How much did depression scores fall?

MADRS scores fell from 25.6 to 2.8 immediately after treatment and 3.8 at one month, with effect sizes of 2.65 and 2.80 [1]. Remission at one month was reported for 83 per cent of participants, an exploratory figure [1].

Has ibogaine been trialled for depression specifically?

No. Depression has been measured as a secondary outcome in studies recruited for other conditions, and a 2026 review notes that the positive efficacy data across the field comes mostly from uncontrolled studies [3].

Did the improvement last?

In the twelve-month follow-up, the estimated probability of sustained remission from depression was 66 per cent [2]. That follow-up is a preprint and has not been peer reviewed [2].

Would someone have to stop their antidepressant first?

In the Stanford protocol, participants stopped all psychiatric medications before treatment, along with several other drug classes [1]. Some antidepressants also lengthen the QT interval or inhibit the enzyme that clears ibogaine, which is why they appear in screening exclusions [4]. Stopping them is a clinical decision with its own risks.

What about suicidal thinking?

Reported suicidal thinking fell from 47 per cent of participants at baseline to none immediately after and 7 per cent at one month [1]. The authors describe this as exploratory and to be interpreted cautiously [1].